COMPASS Pathways Plc · NASDAQ:CMPS
COMPASS Pathways — Investor Presentation (February 2021)
36 slides from COMPASS Pathways's investor presentation, Feb 9, 2021
Slide 1: Transforming mental health care
© COMPASS Pathways 2021 Transforming mental health care COMPASS Pathways plc February 2021
Slide 2: Disclaimer
© COMPASS Pathways 2021 Disclaimer This presentation has been prepared by COMPASS Pathways plc (“we”, “us”, “our”, “COMPASS”, “COMPASS Pathways”, or the “Company”) and contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Except for stateme
Slide 3: COMPASS's leadership team
© COMPASS Pathways 2021 COMPASS’s leadership team George Goldsmith Chairman, CEO and Co-founder Ekaterina Malievskaia, MD Chief Innovation Officer, Co-founder Lars Wilde President, Chief Business Officer, Co-founder Piers Morgan Chief Financial Officer Nate Poulsen General Counsel and Head of Legal,
Slide 4: Everyone has a story
© COMPASS Pathways 20213 3 Everyone has a S T O R Y
Slide 5: We are a mental health care company
© COMPASS Pathways 2021CONFIDENTIAL | © COMPA S Pathways 20 We are a mental health care company 4 Source: 1. Depression and Other Common Mental Disorders: Global Health Estimates and Cleare, A. et al - 2015 -Evidence-based guidelines for treating depressive disorders with antidepressants: A revision
Slide 6: Transforming the patient experience in mental health care
© COMPASS Pathways 2021 Transforming the patient experience in mental health care Our vision A world of mental wellbeing Health systems and payer partnerships Value-based models, real-world evidence Innovative care delivery models Centres of Excellence, digital technologies FDA Breakthrough Therapy
Slide 7: TRD treatment pathway: significant unmet need
© COMPASS Pathways 2021 6 TRD treatment pathway: significant unmet need for 100 million patients Treatment pathway stage New onset depression Major depressive disorder (MDD) Persistent depression Major depressive disorder (MDD) Treatment-resistant depression (TRD) Line of therapy Estimated no of pat
Slide 8: We need a new treatment model in TRD
© COMPASS Pathways 2021 We need a new treatment model in TRD Source: WHO (2017); Depression Therapeutics by David Thomas and Chad Wessel, Bio Industry Analysis (2019); Johnston KM, Powell LC, Anderson IM, Szabo S, Cline S (2018). The burden of treatment- resistant depression: a systematic review of
Slide 9: COMP360 psilocybin therapy: clinical status
© COMPASS Pathways 2021 COMP360 psilocybin therapy: clinical status • Designated Breakthrough Therapy for TRD in 2018 • Preclinical genotoxicity and cardiotoxicity studies completed • Phase I trial completed: COMP360 generally well-tolerated in healthy participants (n=89) • Phase IIb trial in TRD: u
Slide 10: Clinical signals from academic-sponsored trials
© COMPASS Pathways 2021 Clinical signals: early indicators from academic-sponsored trials show rapid reductions in symptoms in TRD and other mental health conditions 9 2011 2016 2016 2016, 2018 UCLA1 Grob et al n = 82 New York University Ross et al n = 232 Johns Hopkins Griffiths et al n = 462 Imper
Slide 11: Psilocybin therapy: potential benefits for patients, clinicians and payers
© COMPASS Pathways 2021 Psilocybin therapy: potential benefits for patients, clinicians and payers Rapid and sustained relief A meaningful patient experience A sense of agency and empowerment Reduction in total cost of care Lower healthcare resource utilisation Increased productivity, reduced absent
Slide 12: Psilocybin is a psychoactive substance
© COMPASS Pathways 2021 Psilocybin is a psychoactive substance 11 An active ingredient in some species of mushrooms Established knowledge of subjective effects A generally well-tolerated serotonergic psychedelic Psilocybin molecule
Slide 13: COMP360 mechanism of action
© COMPASS Pathways 2021 COMP360 mechanism of action 12 Source: 1. Halberstadt et al (2011); 2. Lopez-Gimenez et al (2018); 3. Vollenweider et al (1999); 4. Sakashita et al (2015); 5. Carhart-Harris et al (2012a); 6. Petri (2014); 7. Ly et al (2018) Note: *5-HT2A = 5-hydroxytyryptamine 2A; DMN = defa
Slide 14: Visualisation of acute changes in brain network connectivity
© COMPASS Pathways 2021 Simplified visualisation of the acute changes in brain network connectivity 13 Placebo Psilocybin Brain network alterations may indicate the emergence of novel patterns of connectivity, following downregulation of the DMN Note: Figure adapted from Petri et al, 2014; study ana
Slide 15: Phase I safety and feasibility trial
© COMPASS Pathways 2021 Phase I safety and feasibility trial – data published in December 2019 Note: Study run in conjunction with Institute of Psychiatry, Psychology & Neuroscience, King’s College London Source: 'Eriksson - 2020 - Psilocybin therapy for treatment-resistant depression' and also 'COM
Slide 16: COMP360 induced psychedelic experiences that correlate with therapeutic effect
© COMPASS Pathways 2021 COMP360 induced psychedelic experiences that correlate with therapeutic effect 15 a. Ranked by incidence in the 25mg psilocybin group b. Includes auditory, gustatory, olfactory, tactile and visual hallucinations Most frequently reported AEs* (MedDRA Code) a in our phase I tri
Slide 17: Majority of adverse events resolved on day of administration
© COMPASS Pathways 2021 Majority of adverse events resolved on day of administration, with a median duration of one day 16 Of all AEs, 68% reported as starting and resolving on the day of administration The median duration of AEs in all treatment arms across the 12-week trial was one day Most fr
Slide 18: Psilocybin therapy: preparation, session, integration
© COMPASS Pathways 2021 Integration 17 Psilocybin therapy: described by most patients in one study as being among the top five most meaningful experiences of their lives1 Source: 1.Griffiths et al (2016) Preparation Psilocybin session • Establish therapeutic alliance • Demonstrate and practise self-
Slide 19: COMPASS solutions in development
© COMPASS Pathways 2021 COMPASS solutions in development Patient preparation platform Online therapist training and learning platform AI-assisted therapist feedback and monitoring Research Analyse digital biomarker data with the goal of predicting relapse and modelling disease course Develop technol
Slide 20: A rigorous therapist training programme
© COMPASS Pathways 2021 A rigorous therapist training programme 19 Note: TRD = treatment-resistant depression; 1. Development and Evaluation of a Therapist Training Program for Psilocybin Therapy for Treatment-Resistant Depression in Clinical Research, Sara J Tai, Elizabeth Nielson, Molly Lennard-Jo
Slide 21: Phase IIb clinical trial: COMP360 psilocybin therapy for TRD
© COMPASS Pathways 2021 Phase IIb clinical trial: COMP360 psilocybin therapy for TRD Target enrolment of 216 patients; data expected late 2021 20 Primary endpoint ✧ Reduction of symptoms of depression as measured by MADRS* from Baseline to 3 weeks Secondary endpoint ✧ Proportion of responders who ma
Slide 22: Sites engaged for phase IIb TRD study
© COMPASS Pathways 2021 Sites engaged for phase IIb TRD study have the reputation and capability to recruit patients 21 Site Country with engaged site Groningen London (2) Newcastle Barcelona (2) Aalborg DublinToronto New York City Baltimore Atlanta Houston San Diego (2) Stanford Bristol Utrecht Lei
Slide 23: Our clinical development programme for COMP360 in TRD
© COMPASS Pathways 2021 Our clinical development programme for COMP360 psilocybin therapy in TRD Getting ready for phase III 22 Safety and feasibility 89 healthy volunteers Phase IIIPhase IIPhase I Status Safety and efficacy Primary endpoint: change in MADRS 216 patients, 22 sites in EU, US, Canada
Slide 24: Leader in psilocybin therapy research
© COMPASS Pathways 2021 COMPASS Pathways: leader in psilocybin therapy research 23 IISs using COMP360: signal-generating, exploratory studies looking at indications in areas of unmet need Note: IIS = investigator-initiated studies, MDD = major depressive disorder, TRD = treatment-resistant depressio
Slide 25: Our first Centre of Excellence with Sheppard Pratt
© COMPASS Pathways 2021 Our first Centre of Excellence, in collaboration with Sheppard Pratt, to accelerate research in a range of mental health illnesses One of the world’s leading research institutions in mental health and one of the top psychiatric hospitals in the US A leader in clinical service
Slide 26: COMP360 therapy for major depressive disorder in cancer
© COMPASS Pathways 2021 Exploring the potential of COMP360 therapy for major depressive disorder in cancer with Maryland Oncology Hematology at the Aquilino Cancer Center Signal-generating study (IIS) Major depressive disorder in cancer - an unmet medical need Purpose-built facility A 30-patient, op
Slide 27: COMPASS Pathways Discovery Center
© COMPASS Pathways 2021 COMPASS Pathways Discovery Center A collaboration among world-leading scientists and institutions 26 John D McCorvy, leading 5-HT receptor pharmacologist and expert on GPCR signalling • Assistant Professor, Department of Cell Biology, Neurobiology and Anatomy, Medical College
Slide 28: Comprehensive preclinical program across a broad range of indications
© COMPASS Pathways 2021 Comprehensive preclinical program - COMP360 psilocybin in a broad range of indications with pending patent applications 27 Preclinical research has been conducted in the following indication areas: Ongoing confidence in these biological substrates builds preclinical extrapola
Slide 29: COMP360 commercial exclusivity strategy
© COMPASS Pathways 2021 COMP360 commercial exclusivity strategy First US patent granted in December 2019 • Claims directed to methods of treating drug-resistant depression with high-purity polymorphic crystalline psilocybin • Petition for Post Grant Review was dismissed on merits in August 2020 28 E
Slide 30: Achieving broad patient access
© COMPASS Pathways 2021 Achieving broad patient access • Early scientific advice with key payer-experts and HTAb* • US reimbursement and coding strategy • Real-world evidence - data access agreements • Centres of Excellence • Prospective payer-focused trials • Potential franchise model Comprehensive
Slide 31: Financial overview
© COMPASS Pathways 2021 Financial overview Cash and cash equivalents at 30 September 2020 • $196.5 million IPO raise • $146.6 million1 Issued shares • 35,930,331 Covering analysts • Ritu Baral, Cowen • Josh Schimmer, Evercore • Esther Hong, Berenberg • Sumant Kulkarni, Canaccord Genuity • Patrick Tr
Slide 32: A strong and growing team
© COMPASS Pathways 2021 31 A strong and growing team
Slide 33: Backed by high calibre boards
© COMPASS Pathways 2021 Backed by high calibre boards Board of directors George Goldsmith Ekaterina Malievskaia, MD Florian Brand Jason Camm Annalisa Jenkins, MBBS Thomas Lönngren Linda McGoldrick Robert McQuade, PhD David Norton Scientific advisory board Prof David Nutt, MD, PhD Gül Dölen, MD, PhD
Slide 34: Pioneering the development of a new model of psilocybin therapy
© COMPASS Pathways 2021 Pioneering the development of a new model of psilocybin therapy 2021 Anticipated milestones Establish first Centre of Excellence Phase IIb trial: data expected late 2021 Further senior appointments Further partnerships and collaborations Data published from IISs usi
Slide 35: Participant quote
© COMPASS Pathways 2021 I had such instant relief I could make up my mind about things … it lifted the fog of depression. The way I felt after, I have not felt with any medicine or therapy … I forgot what depression was. Quote from participant in Imperial College London psilocybin therapy study cond
Slide 36: Stephen Schultz, SVP Investor Relations
© COMPASS Pathways 2021 Stephen Schultz SVP, Investor Relations stephen.schultz@compasspathways.com +1 401-290-7324
COMPASS Pathways — Investor Presentation (February 2021) on 6ix